CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC 1295 No DAC Ipamorelin Research Australia Explained

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

60 WORDS

Short answer

The most common failure point in growth hormone secretagogue work isn't the blend ratio or the receptor pharmacology. It's the freezer door. Lyophilised peptide holds up well at -20°C, but a blend vial that's been thawed, drawn from and refrozen five times is no longer the material described on the certificate of analysis, and nothing downstream in the assay will…

Key takeaways

CJC-1295 no DAC is modified GRF (1-29), a 29-amino-acid GHRH analog with four substitutions that resist DPP-4 cleavage, and it clears in roughly 30 minutes rather than days.
Ipamorelin is a pentapeptide GHS-R1a agonist, and the 1998 Raun paper characterised it as selective, with little prolactin or ACTH response in the models studied.
The blend rationale is two separate second-messenger pathways converging on the same somatotroph, which is why combined GHRH plus GHRP research reports release exceeding either compound alone.
Choosing DAC over no DAC changes the experiment from pulsatile signalling to sustained exposure, so the version determines which question the data can answer.
Peptide adsorption to glass and polypropylene at dilute working concentrations causes more between-lab variance than purity differences do.
Every compound discussed here is research-use-only material, not approved for human or veterinary consumption, and import rules vary by jurisdiction.

Labs running CJC 1295 no DAC ipamorelin research Australia-side ask our team the same three things: why pair a GHRH analog with a ghrelin receptor agonist at all, why pick the no-DAC version over the long-acting one, and where tesamorelin fits into the picture.

What is the CJC 1295 no DAC + ipamorelin research blend?

CJC 1295 no DAC ipamorelin research Australia inquiries almost always concern one catalog format: a research-use-only vial pairing modified GRF (1-29) with the pentapeptide ipamorelin, commonly at 5mg/5mg. The two compounds act on separate pituitary receptors, which is why the literature reports greater growth hormone release from the pair than from either compound alone.

The word vendor copy usually gets wrong is 'stronger'. The blend isn't a larger dose of one signal. It's a different signal shape, because a GHRH analog raises what somatotrophs are capable of releasing while ipamorelin triggers the release itself and reduces somatostatin braking. What follows covers the receptor mechanisms, why the DAC and no-DAC versions answer different experimental questions, how tesamorelin blends differ, and the handling errors that wreck more datasets than purity ever has.

Two receptors, one cell type: why the pairing exists

The blend works on the anterior pituitary somatotroph from two directions at once, and that's the entire rationale. CJC-1295 without DAC is modified GRF (1-29), a 29-amino-acid fragment of growth hormone releasing hormone carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that slow cleavage by dipeptidyl peptidase-4, the enzyme that chews through native GHRH within minutes. It binds the GHRH receptor, a Gs-coupled receptor, raising cyclic AMP, activating protein kinase A, and increasing both GH gene transcription and the releasable pool.

Ipamorelin does something different. It's a pentapeptide agonist at GHS-R1a, the ghrelin receptor, which signals through phospholipase C and inositol trisphosphate to raise intracellular calcium and push stored GH vesicles out by exocytosis. It also blunts somatostatin, the inhibitory hormone that normally clamps secretion between pulses.

Two separate second-messenger pathways converging on one cell is why combined GHRH plus GHRP research repeatedly reports release greater than the sum of each compound given alone, an effect first mapped in the growth hormone releasing peptide work of Bowers and colleagues. Ipamorelin's other distinguishing feature comes from the 1998 European Journal of Endocrinology paper by Raun and colleagues that introduced it as a selective secretagogue, with little of the prolactin and ACTH response seen with GHRP-6 or hexarelin in the models tested.

In our experience fielding questions on this pairing, researchers grasp the synergy quickly. What they underestimate is how much the half-life of the GHRH arm changes the experiment.

The half-life question that decides which CJC you actually want

No DAC and with DAC are not two grades of the same product. They're two different pharmacokinetic tools. DAC stands for drug affinity complex, a maleimide linker that binds covalently to albumin in circulation; the 2006 Journal of Clinical Endocrinology and Metabolism study by Teichman and colleagues reported a multi-day elimination profile and sustained IGF-1 elevation from that version. Modified GRF (1-29) without the DAC clears in the region of 30 minutes.

That gap matters because growth hormone secretion is pulsatile, not continuous. A GHRH signal that persists for days flattens pulse architecture and interacts awkwardly with the somatostatin rhythm, so models built to study pulse frequency, amplitude or trough recovery use the short-acting form. Sustained-exposure designs use DAC. Picking the wrong one doesn't produce a weaker result, it produces a result that answers a question nobody asked.

Here's the part most sourcing guides skip entirely. At the dilute working concentrations typical of in vitro work, peptides adsorb onto borosilicate glass and polypropylene surfaces, and the proportional loss is far larger in a dilute aliquot than a concentrated one. Two labs can draw from the same CJC-1295 no DAC vial, report different apparent activity, and both be handling genuinely identical material. Reconstitution technique compounds it: firing diluent straight onto the lyophilised cake foams the solution and shears peptide, whereas running the stream down the vial wall and swirling doesn't. Aliquot once, freeze once, and stop blaming purity for variance that's really surface chemistry.

Tesamorelin blends, regulatory status, and reading a certificate properly

Tesamorelin is the most clinically characterised GHRH analog of the group, which is precisely why the tesamorelin ipamorelin research blend now sits alongside the cjc 1295 ipamorelin research peptides in most catalogs. It's a 44-amino-acid GHRH analog carrying a trans-3-hexenoyl group at the N-terminus that resists protease degradation, and it's the active ingredient in a prescription product authorised for HIV-associated lipodystrophy. A research vial is not that finished drug product, and it isn't approved for any use in people or animals.

Regulatory position is the first thing CJC 1295 no DAC ipamorelin research Australia-based teams should verify, because research-use-only labelling is a description of intended use, not an import permission. Growth hormone secretagogues, including GHRH analogues and GHRPs, sit on the World Anti-Doping Agency prohibited list under the S2 peptide hormone category, and national import rules for these compounds differ significantly. Verify with your own regulator before any cross-border order. Nothing here is dosing, administration or protocol guidance. If you have a personal health question about growth hormone physiology, raise it with a physician, and if it concerns an animal, talk to your veterinarian.

On documentation: a usable certificate names the lot, shows HPLC purity with the chromatogram, confirms identity by mass spectrometry against the theoretical molecular weight, and reports water content from the lyophilisation step. For blends, it should verify both sequences, not just one. Our team publishes lot documentation openly in the certificates of analysis library, and researchers comparing formats can review the CJC-1295 and ipamorelin 5mg/5mg blend, single-compound ipamorelin, tesamorelin, the tesamorelin and ipamorelin stack, or the wider research catalog side by side.

How the GHRH and GHRP options compare

The practical differences between these compounds are pharmacokinetic and structural, not a question of one being better. This table maps what each one is suited to.

Compound	Primary receptor target	Reported half-life	Common research role	Bottom line
CJC-1295 no DAC (modified GRF 1-29)	GHRH receptor on anterior pituitary somatotrophs	Short, reported in the region of 30 minutes	Pulsatile GHRH signalling models needing a brief, defined stimulus	The default GHRH arm whenever pulse shape rather than sustained exposure is the variable
CJC-1295 with DAC	Same GHRH receptor, circulating bound to albumin via the drug affinity complex	Days rather than minutes, per the 2006 JCEM pharmacokinetic study	Sustained IGF-1 elevation and infrequent-administration designs	Suited to continuous exposure work, unsuitable if pulsatility is being measured
Ipamorelin	GHS-R1a, the ghrelin receptor	Short, on the order of tens of minutes	Selective GHRP arm or secretagogue control	Characterised in 1998 as selective, with minimal prolactin and ACTH response in the models tested
Tesamorelin	GHRH receptor, stabilised 44-amino-acid analog	Longer than native GHRH due to the trans-3-hexenoyl modification	Visceral adipose tissue and lipodystrophy models	The most clinically documented GHRH analog here, though a research vial is not the approved drug product
CJC-1295 no DAC + ipamorelin 5mg/5mg blend	Both receptor systems simultaneously	Both arms clear quickly	Combined secretagogue and synergy designs	Convenient at a fixed ratio; separate vials stay preferable when the ratio itself is the variable

What If: Handling and Sourcing Scenarios

What if the blend vial sat at ambient temperature during a long shipping delay?

Check the lyophilised cake before doing anything else and record the condition against the lot number. Lyophilised peptide is considerably more tolerant of short ambient excursions than reconstituted solution, which is why suppliers ship powder rather than liquid, but heat and humidity both matter. A cake that has collapsed, gone sticky or turned from white to yellow indicates moisture ingress or degradation, and material in that state shouldn't enter a study as a known input. Refrigerated storage on arrival, then -20°C, remains standard practice.

What if two aliquots from the same vial give different results?

Audit the dilution and container path before suspecting the peptide. Surface adsorption, freeze-thaw cycling and foaming during reconstitution each remove active material without altering anything a purity assay would detect afterwards. Aliquoting into low-binding tubes immediately after reconstitution, keeping a single thaw per aliquot, and holding working concentrations consistent across arms eliminates most of this variance. If it persists after that, request the chromatogram for the specific lot.

What if a supplier can't produce lot-specific documentation?

Treat a missing or generic certificate as a disqualifying fact rather than an inconvenience. A certificate that names no lot number, shows no chromatogram, or has been reused across batches tells you nothing about the vial in your hand, and for a two-compound blend it must confirm both sequences by mass spectrometry. Purity claims without an accompanying analytical trace are marketing text, and unverified material makes every downstream result unciteable.

The honest truth about blend potency claims

Let's be direct about this: no supplier can tell you that one CJC 1295 ipamorelin research blend outperforms another, and any copy suggesting otherwise is inventing a comparison nobody has run. The mg/mg ratio on the label is a formulation choice, not evidence. What genuinely separates one vial from the next is verifiable HPLC purity, mass spectrometry identity confirmation on that specific lot, and a cold chain that didn't break. Everything else is packaging. These compounds have no approved use in people or animals, and cjc 1295 and ipamorelin research results reported in the literature describe models, not outcomes any reader should expect.

CJC 1295 no DAC ipamorelin research Australia or anywhere else ultimately turns on something unglamorous: whether the material in the vial on study day is the material described on the paperwork. Receptor pharmacology is settled enough that two pathways converging on the somatotroph is no longer a controversial premise. Documentation and handling are where reproducibility is actually won or lost, and a chromatogram tied to a lot number does more for a dataset than any refinement of the ratio ever will.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Because most of the published literature examines the two mechanisms separately rather than the fixed-ratio blend. GHRH analogues and growth hormone releasing peptides each have decades of pharmacology behind them, and combined GHRH plus GHRP synergy is documented, but the specific 5mg/5mg blend format is a supply convention rather than a studied drug product. Searching the individual compound names returns far more primary literature than the blend phrase does.

Import rules for peptide hormones vary considerably by country, and research-use-only labelling does not by itself grant importation rights. Researchers outside the supplier's home jurisdiction should confirm requirements with their own national regulator before placing a cross-border order. Growth hormone secretagogues also sit on the World Anti-Doping Agency prohibited list under the S2 category, which is separate from import law but relevant to institutional policy.

DAC is a drug affinity complex, a linker that binds the peptide covalently to circulating albumin and extends its presence to a multi-day profile. Without DAC, the compound is modified GRF (1-29) and clears in roughly 30 minutes. They target the same GHRH receptor, but one models sustained exposure and the other models a brief pulsatile stimulus, so they are not interchangeable in study design.

Ipamorelin is a pentapeptide agonist at GHS-R1a, the ghrelin receptor, and the 1998 European Journal of Endocrinology paper by Raun and colleagues described it as selective, with little of the prolactin and ACTH response reported for GHRP-6 and hexarelin. That selectivity is why it is often chosen as the GHRP arm in combined secretagogue models where confounding hormone responses would muddy the readout.

A 5mg/5mg blend vial contains 5 milligrams of CJC-1295 no DAC and 5 milligrams of ipamorelin lyophilised together in a single container. The certificate of analysis should confirm both sequences independently by mass spectrometry and report HPLC purity for the lot. If the documentation only verifies one of the two compounds, it is incomplete for a blend.

Lyophilised peptide is typically held at -20°C protected from light and moisture, with refrigeration at 2–8°C acceptable for shorter holding periods. Once reconstituted, solution is refrigerated and aliquoted so that each portion is thawed only once. Repeated freeze-thaw cycling is one of the most common and most invisible causes of lost activity, because it degrades material without changing the vial's appearance.

It pairs tesamorelin, a stabilised 44-amino-acid GHRH analog carrying a trans-3-hexenoyl modification that resists protease degradation, with the ghrelin receptor agonist ipamorelin. The design logic mirrors the CJC blend: one compound acting at the GHRH receptor, the other at GHS-R1a. Tesamorelin is the most clinically characterised GHRH analog of the group, though a research vial is not the approved prescription product that shares the ingredient.

No. CJC-1295 no DAC, ipamorelin and research-grade tesamorelin are supplied as research-use-only materials and are not approved drug products for people or animals. Nothing about them should be read as dosing, administration or protocol guidance. Health questions belong with a licensed physician, and animal health questions with a veterinarian.

Neither is better in the abstract; they suit different designs. A blend vial fixes the ratio, which reduces handling steps and preparation error when that ratio is not the variable being tested. Separate vials are the right choice when the study varies the GHRH to GHRP ratio, uses one compound as a control arm, or needs different storage timelines for each.

Pricing varies widely by supplier, vial size and the depth of analytical documentation provided, so comparing on a per-milligram basis with the certificate of analysis in hand is more useful than comparing headline prices. Small-batch synthesis, third-party HPLC and mass spectrometry verification, and cold chain shipping all add cost. Material sold without lot-specific documentation is cheaper for a reason.

The three practical risks are misidentification, degradation and contamination. Misidentification is addressed by mass spectrometry confirmation against the theoretical molecular weight; degradation by strict temperature control and single-thaw aliquoting; and contamination by aseptic reconstitution technique. Peptide adsorption to glass and polypropylene surfaces is a fourth, quieter risk that silently reduces effective concentration in dilute preparations.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA